Investec restated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note published on Wednesday morning. Investec currently has a GBX 1,800 ($23.45) price target on the stock.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC cut their target price on shares of GlaxoSmithKline plc from GBX 1,850 ($24.10) to GBX 1,800 ($23.45) and set a buy rating on the stock in a research note on Thursday, April 20th. Liberum Capital reiterated a buy rating and set a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, March 30th. HSBC Holdings plc reiterated a buy rating and set a GBX 1,970 ($25.66) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, April 27th. Beaufort Securities reiterated a buy rating and set a GBX 1,750 ($22.80) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, April 27th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research note on Thursday, April 27th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of GBX 1,734.73 ($22.60).

GlaxoSmithKline plc (LON:GSK) opened at 1518.50 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The firm’s 50 day moving average price is GBX 1,638.77 and its 200 day moving average price is GBX 1,627.17. The stock’s market cap is GBX 74.22 billion.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (LON:GSK) Receives Buy Rating from Investec” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-longsk-receives-buy-rating-from-investec/1462336.html.

The business also recently announced a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be given a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a yield of 1.23%.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga purchased 2,267 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Also, insider Patrick Vallance purchased 861 shares of the company’s stock in a transaction dated Friday, July 14th. The shares were acquired at an average price of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). In the last quarter, insiders acquired 3,150 shares of company stock valued at $5,054,075.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.